Phase 1 N=39 IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Cancer
Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
Phase 2 N=12 Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Solid Malignancy · Solid Tumor
Primary: Response Rate (RR) — 1 Participants
Phase 1 N=18 HCW9218 in Select Advanced Solid Tumors
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Phase 2 N=474 A Study of Atezolizumab in Advanced Solid Tumors
Tumors
Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 2 N=50 Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Phase 1 N=191 Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Solid Tumor
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 59; 20; 21; 21 Participants
Phase 1 N=19 Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
Advanced Solid Tumor · Lung Cancer · Pancreas Cancer
Primary: Safety and Tolerability Assessment of CNSI-Fe(II) — 0; 0; 1; 0 Participants
Phase 2 N=57 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
Oncology · MET Gene Amplification · NSCLC
Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs
Phase 2 N=29 M6620 (VX-970) in Selected Solid Tumors
Solid Tumor · Leiomyosarcoma · Osteosarcoma
Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change
Phase 1 N=51 Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
Neoplasms
Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Part 1 — 0; 0; 1; 1 participants
Phase 1 N=78 Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
Neoplasms
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 4; 4; 4; 4 Participants
Phase 1 N=57 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
Solid Tumors
Primary: Dose-escalation Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Participants
Phase 1 N=24 Weekly BI 836880 in Patients With Advanced Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
Phase 1 N=116 A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Advanced Solid Tumors · Advanced Recurrent Ovarian Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 1; 2; 1 Participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 1 N=43 A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 4; 3; 13; 3 Participants
Phase 1 N=27 Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Advanced Solid Tumors
Primary: Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases) — 0…
Phase 2 N=345 Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Advanced Solid Tumors
Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 1 N=39 A Phase 1 Study in Patients With Solid Tumors
Solid Tumors
Primary: Recommended Phase 2 Dose
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=48 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
Phase 1 N=23 A Study Of PF-04449913 Administered Alone In Select Solid Tumors
Solid Tumors
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 0; 0; 2 Participants
Phase 2 N=33 Radiotherapy for Solid Tumor Spine Metastases
Solid Tumor Spine Metastases
Primary: Number of Participants With Radiographic Recurrence at 12 Months — 3 Participants
Phase 2 N=130 A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Tumors
Primary: Dose-Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
Phase 1 N=34 AZD1775 for Advanced Solid Tumors
Solid Tumors
Primary: To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors — 6; 4; 6; 3 Participants
N/A N=12 Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
Cervical · Ovarian · Lung
Primary: Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition — 71.9 percent increase sestamibi retention
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events